ALEMBIC PHARMACEUTICALS LTD. - 533573 - Alembic Pharmaceuticals Ltd reply to clarification sought by the exchange
The Exchange has sought clarification from Alembic Pharmaceuticals Ltd with respect to news article appearing on www.financialexpress.com May 25, 2021titled "Alembic gets Gujarat FDCA licence for anti-black fungal drug Amphotericin-B".Alembic Pharmaceuticals Ltd response is enclosed. Alembic Pharmaceuticals Ltd - 533573 - Clarification sought from Alembic Pharmaceuticals Ltd
The Exchange has sought clarification from Alembic Pharmaceuticals Ltd with respect to news article appearing on www.financialexpress.com May 25, 2021titled "Alembic gets Gujarat FDCA licence for anti-black fungal drug Amphotericin-B".The reply is awaited.
Hold Alembic Pharma: target of Rs 1055: ICICI Direct
ICICI Direct recommended hold rating on Alembic Pharma with a target price of Rs 1055 in its research report dated May 05, 2021. Alembic Pharmaceuticals Ltd - 533573 - Disclosure Of Related Party Transactions For The Half Year Ended 31St March, 2021
Pursuant to Regulation 23(9) of the Listing Regulations, 2015, we enclose herewith Disclosure of Related Party Transactions, on a consolidated basis, for the half year ended 31st March, 2021.
Alembic Pharmaceuticals gets USFDA nod for bipolar depression drug
Drug firm Alembic Pharmaceuticals on Friday said it has received final approval from the US health regulator for Lurasidone Hydrochloride tablets, used to treat bipolar depression. The approved product is therapeutically equivalent to the reference listed drug product (RLD) Latuda tablets of Sunovion Pharmaceuticals Inc. The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Lurasidone Hydrochloride tablets in the strengths of 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg, Alembic Pharmaceuticals said in a regulatory filing. Quoting IQVIA data, Alembic Pharma said Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg have an estimated market size of USD 3.7 billion for the twelve months ending December 2020. Lurasidone Hydrochloride tablets are indicated for treatment of major depressive episodes associated with bipolar I disorder (bipolar depression). Alembic Pharma said it has settled the cas Alembic Pharmaceuticals Ltd - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Lurasidone Hydrochloride Tablets, 20 mg, 40 mg, 60 mg, 80 mg, and 120 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
With reference to our intimation dated 27th April, 2021 regarding schedule of Post Results Conference Call, please find enclosed herewith the transcript of the said Conference Call held on 4th May, 2021. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the Listing Regulations, 2015, we enclose herewith a copy of Notice w.r.t. transfer of Equity Shares of the Company to Investor Education and Protection Fund (IEPF) published in English and vernacular language (Gujarati) newspaper on 12th May, 2021 in Economic Times English Edition and Financial Express Gujarati Edition. We request you to kindly take the same on record. ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the management of the Company shall be meeting analysts/investors through Virtual Asia Healthcare Conference hosted by Morgan Stanley on 13th May, 2021. We request you to kindly take the same on record. Alembic Pharmaceuticals Ltd - 533573 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/27/2019 dated 8th February, 2019, please find enclosed herewith the Annual Secretarial Compliance Report issued by M/s. Samdani Shah & Kabra, Practicing Company Secretaries, for the financial year ended 31st March, 2021. We request you to kindly take the same on record.